Two Opdivo -based therapies are now authorized for first-line treatment of patients with advanced renal cell carcinoma in the European Union: Opdivo plus Yervoy in combination with Cabometyx Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo Cabometyx ® (cabozantinib) for the first-line treatment of adults with advanced renal cell carcinoma (RCC). The EC’s decision is based on results from the Phase 3 CheckMate -9ER trial, which demonstrated superior efficacy with Opdivo in combination with Cabometyx versus sunitinib across three key endpoints: progression-free survival (PFS), the primary endpoint, and objective response rate (ORR) and overall survival (OS). The combination of
5 неоспоримых преимуществ Tesla - Telegraf by
telegraf.by - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from telegraf.by Daily Mail and Mail on Sunday newspapers.
Ocuphire Announces MIRA-2 Phase 3 Registration Trial for the Reversal of Mydriasis Meets Primary Endpoint
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Быстрее, безопаснее, эффективнее: сравниваем российские вакцины от коронавируса
gazeta.a42.ru - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gazeta.a42.ru Daily Mail and Mail on Sunday newspapers.
Posted on 755
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented preliminary data from the dose-escalation portion of its ARC-8 Phase 1/1b study, evaluating the safety and tolerability of AB680, the first small-molecule CD73 inhibitor to enter the clinic, in metastatic pancreatic cancer at the ASCO 2021 Virtual Gastrointestinal Cancers Symposium (ASCO GI).
The ongoing, open-label, multicenter trial is a Phase 1/1b study evaluating the safety profile and clinical activity of AB680 in combination with nab-paclitaxel plus gemcitabine (NP/Gem) and zimberelimab, an anti-PD-1 antibody, as a first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).